Articles tagged "FK506"

2020 American Transplant Congress
Imaging OX40+Alloreactive T Cells Provides Early Warning of Organ Transplant Rejection
T. Hirai¹, A. Mayer², T. W. Nobashi², Z. Xiao², T. Udagawa³, K. Seo⁴, F. Simonetta⁵, J. Baker⁵, A. Cheng³, S. S. Gambhir², R. S. Negrin⁵
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Radiology, Stanford University, Stanford, CA, ³Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, ⁴Division of Cardiovascular Medicine, Stanford University, Stanford, CA, ⁵Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA
*Purpose: Diagnosis of organ transplant rejection relies upon biopsy approaches to confirm alloreactive T cell infiltration in the graft. Immuno positron emission tomography (immunoPET) utilizing…
2020 American Transplant Congress
Trust and Transparency in Artificial Intelligence-Aided Immunosuppression Decisions
J. Clement
Information and Decision Sciences, University of Minnesota, Minneapolis, MN
*Purpose: In transplant, there is significant interest in using Artificial Intelligence (including machine learning or predictive models) Clinical Decision Support Systems(AI CDSS). Properly designing and…
2020 American Transplant Congress
Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients
D. Nnani¹, A. Campbell¹, M. Ajaimy², S. R. Patel³, O. Saeed³, D. J. Goldstein⁴, J. Graham⁵, U. P. Jorde³
¹Pharmacy, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, ⁴Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, ⁵Surgery, Montefiore Medical Center, Bronx, NY
*Purpose: An innovative strategy to meet the demands of patients requiring heart or kidney transplantation is the acceptance of hepatitis C viremic organs. Direct acting…
2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
J. Banbury¹, A. Dodson¹, C. Lin², K. Gutierrez¹
¹University of Alabama at Birmingham Hospital, Birmingham, AL, ²Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…
2020 American Transplant Congress
Early Calculation of the Tacrolimus Concentration-to-Dose Ratio Does Not Predict Outcomes after Renal Transplantation
K. Schütte-Nütgen, I. Bartmann, B. Suwelack, S. Reuter
Department of Internal Medicine D, University Hospital Münster, Münster, Germany
*Purpose: There is emerging interest in the concentration-to-dose (C/D) ratio of tacrolimus (Tac) as it is linked to outcomes after renal transplantation (RTx). Recently, we…
2020 American Transplant Congress
Clinical Implications of Tacrolimus Time in Therapeutic Range in Urban Renal Transplant Recipients Under an Early Corticosteroid Withdrawal Protocol
D. Pierce, P. West-Thielke, Z. Hajjiri, S. Gaitonde, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus displays wide inter- and intra-patient variability, necessitating therapeutic drug monitoring. Assessing the duration of time in therapeutic range (TTR) is an additional tool…
2020 American Transplant Congress
Specific Gut Microbiota Community Suppresses Acute Rejection by Reducing Natural Killer Cell Population
W. Zhang, L. Gong, Y. Xu, X. Hu
Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Urology Institute of Capital Medical University, Beijing, China
*Purpose: The gut microbiota community was reported to be altered by high-dose FK506 treatment, while fecal microbiota transplantation with such microbiota plus low-dose FK506 could…
2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
C. Doligalski¹, K. Walter¹, P. Chang², L. J. Lobo²
¹University of North Carolina Medical Center, Chapel Hill, NC, ²Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…
2020 American Transplant Congress
Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells
H. J. Jang
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…
2019 American Transplant Congress
Eupatilin Ameliorates Tacrolimus Induced Nephrotoxicity via Inhibiting Apoptosis
H. J. Jang, C. S. Park, M. Y. Oh
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…